Cell Metabolism:激素治疗糖尿病,激素

2012-07-06 Beyond 生物谷

近日,杜克大学医学中心研究人员发现激素可以像胰岛素那样由胰腺中的胰岛细胞产生,产生的激素具有保护功效、抗糖尿病的功能。发现新的激素能刺激老鼠和人类胰岛细胞胰岛素的分泌,能保护胰岛细胞免受毒性因子、细胞杀伤因子的损害。 这项最新研究刊登在7月3日的Cell Metabolism杂志上。 研究人员给予TLQP-21朱克糖尿病脂肪老鼠激素,这种老鼠有罹患2型糖尿病的遗传倾向。研究结果给予激素的老鼠体

近日,杜克大学医学中心研究人员发现激素可以像胰岛素那样由胰腺中的胰岛细胞产生,产生的激素具有保护功效、抗糖尿病的功能。发现新的激素能刺激老鼠和人类胰岛细胞胰岛素的分泌,能保护胰岛细胞免受毒性因子、细胞杀伤因子的损害。

这项最新研究刊登在7月3日的Cell Metabolism杂志上。

研究人员给予TLQP-21朱克糖尿病脂肪老鼠激素,这种老鼠有罹患2型糖尿病的遗传倾向。研究结果给予激素的老鼠体内胰岛素和葡萄糖(血糖)水平显著提高,β细胞死亡减少。

该研究还证实TLQP-21在葡萄糖存在的情况下能防止β细胞恶化,刺激胰岛素分泌。β细胞的数量不断减少和胰岛素产生下降便会出现糖尿病,因此寻找最好的方式来产生这种具有保护作用的激素可能是有价值的。

虽然到目前为止,研究人员只测试了TLQP-21在2型糖尿病模型中的作用,但他们计划在未来研究中测试激素在1型糖尿病中的作用。

TLQP-21 是一种生物活性肽,来源于神经分泌蛋白VGF的特定区域,按神经生长因子反应基因的编码。TLQP-21调节代谢,增加BM水平,刺激肾上腺髓质,调节胃部动力功能,阻止体重增加。

研究人员下一步的工作就是要找到一个小分子可以刺激胰岛细胞产生更多的TLQP-21激素。

doi:10.1016/j.cmet.2012.01.024
PMC:
PMID:

Interplay between Lipids and Branched-Chain Amino Acids in Development of Insulin Resistance

Christopher B. Newgard

Fatty acids (FA) and FA-derived metabolites have long been implicated in the development of insulin resistance and type 2 diabetes. Surprisingly, application of metabolomics technologies has revealed that branched-chain amino acids (BCAA) and related metabolites are more strongly associated with insulin resistance than many common lipid species. Moreover, the BCAA-related signature is predictive of incident diabetes and intervention outcomes and uniquely responsive to therapeutic interventions. Nevertheless, in animal feeding studies, BCAA supplementation requires the background of a high-fat diet to promote insulin resistance. This Perspective develops a model to explain how lipids and BCAA may synergize to promote metabolic diseases.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2013-02-18 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2012-07-10 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2013-04-07 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1887323, encodeId=3b9e188e32365, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 07:10:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868551, encodeId=c086186855166, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 13 14:10:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958783, encodeId=88e91958e831d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 10 17:10:00 CST 2012, time=2012-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895631, encodeId=e5d318956319d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 07 01:10:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307322, encodeId=3c62130e3226a, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577136, encodeId=a23f15e713634, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597911, encodeId=fc9c159e911f8, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2012-07-08 闆锋旦

相关资讯

J Mol Cell Biol:徐鹰等发现低氧可以驱动癌症生长

Journal of Molecular Cell Biology(《分子细胞生物学报》)2012年第3期“复杂疾病的系统生物学研究”专辑中发表了一篇美国佐治亚大学生物化学与分子生物学系徐鹰教授关于“Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive

Cell Host & Micro:腺病毒逃脱干扰素介导的天然免疫反应的机制

近日,来自劳森健康研究所和西方大学的研究者发现腺病毒在机体免疫反应中扮演着重要作用,相关研究成果刊登在了国际著名杂志Cell Host & Microbe上。腺病毒感染常常引发轻微的呼吸系统疾病,最终引发咳嗽和喉痛等症状。然而当1960年研究者发现腺病毒还可以引发啮齿类动物患瘤,从此研究者才对腺病毒进行了深入研究。肿瘤的产生是因为腺病毒使得细胞分裂不受控制,而且腺病毒可以逃脱免疫系统的监视

Cell Metab:日研究阐明非酒精性脂肪肝发病机制

7月4日,日本横滨市立大学和大阪大学的联合研究小组宣布,他们首次弄清了非酒精性脂肪肝的发病机制。他们确认,一些肥胖者的肝脏会与肠内的细菌发生过敏反应,从而导致肝部发病。 非酒精性脂肪肝多由肥胖引起。它是指患者无饮酒史,但病理学上和酒精性脂肪肝患者有相似的病理状态,比如也有肝细胞脂肪变性、肝小叶炎症,有时也有“酒精”玻璃样变性和肝纤维化等。 研究人员在动物实验中发现,实验鼠肥胖后,脂肪细胞大量分

Cell Death & Differ:时玉舫等间充质干细胞介导的免疫调节获进展

间充质干细胞(MSCs)是在机体内广泛存在的一种具有多向分化潜能的组织干细胞。更由于其具有重要的免疫调节作用而受到重视,近些年来在疾病模式动物模型和临床研究上MSCs被尝试应用于治疗免疫紊乱疾病。尽管有不少文章报道称MSCs有非常良好的治疗效果,但是其治疗适应症、诊疗时机选择和作用机制等有待进一步研究。 最近,《Cell Death & Differentiation》杂志在线发表了中科

Cell:宿主特异性微生物丛诱导免疫系统成熟

6月21日,Cell杂志报道了宿主特异性微生物丛在诱导免疫系统成熟过程中作用的重要研究进展。 肠道微生物诱导宿主的免疫系统成熟,充分体现了宿主 - 微生物共生关系。研究者移植小鼠微生物丛(MMB)或人类微生物丛(HMB)到无微生物(GF)小鼠小肠中,以确定是否小肠免疫成熟取决于宿主特异性的微生物共同进化。 研究显示,肠道细菌的数量和细菌分类门 (phylum)的丰度在MMB和HMB小鼠小肠中是

Cell:张旭等发现调控大脑发育的新机理

《细胞》(Cell)杂志于2012年6月22日发表了上海生科院神经所张旭研究组题为“成纤维细胞生长因子13作为微管稳定蛋白调控神经元极性化与迁移”的研究论文。论文报道了非分泌型成纤维细胞生长因子13(Fibroblast growth factor 13;FGF13)在神经元轴突的生长锥中具有聚合和稳定微管的功能,影响轴突和前导突起的生长;在脑发育过程中FGF13调控神经元的迁移、大脑皮层和海马组